Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E. Ashraf Y, et al. Among authors: jarlier m. J Immunother Cancer. 2019 Feb 4;7(1):29. doi: 10.1186/s40425-019-0498-z. J Immunother Cancer. 2019. PMID: 30717773 Free PMC article.
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T. Lazrek Y, et al. Among authors: jarlier m. Neoplasia. 2013 Mar;15(3):335-47. doi: 10.1593/neo.121960. Neoplasia. 2013. PMID: 23479511 Free PMC article.
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
Boudousq V, Bobyk L, Busson M, Garambois V, Jarlier M, Charalambatou P, Pèlegrin A, Paillas S, Chouin N, Quenet F, Maquaire P, Torgue J, Navarro-Teulon I, Pouget JP. Boudousq V, et al. Among authors: jarlier m. PLoS One. 2013 Jul 29;8(7):e69613. doi: 10.1371/journal.pone.0069613. Print 2013. PLoS One. 2013. PMID: 23922757 Free PMC article.
Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects.
Paillas S, Ladjohounlou R, Lozza C, Pichard A, Boudousq V, Jarlier M, Sevestre S, Le Blay M, Deshayes E, Sosabowski J, Chardès T, Navarro-Teulon I, Mairs RJ, Pouget JP. Paillas S, et al. Among authors: jarlier m. Antioxid Redox Signal. 2016 Sep 10;25(8):467-84. doi: 10.1089/ars.2015.6309. Epub 2016 Jul 5. Antioxid Redox Signal. 2016. PMID: 27224059 Free PMC article.
FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
Marzi L, Combes E, Vié N, Ayrolles-Torro A, Tosi D, Desigaud D, Perez-Gracia E, Larbouret C, Montagut C, Iglesias M, Jarlier M, Denis V, Linares LK, Lam EW, Martineau P, Del Rio M, Gongora C. Marzi L, et al. Among authors: jarlier m. Br J Cancer. 2016 Nov 8;115(10):1223-1233. doi: 10.1038/bjc.2016.313. Epub 2016 Sep 29. Br J Cancer. 2016. PMID: 27685445 Free PMC article.
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet JM, Pèlegrin A, Larbouret C, Robert B. Leconet W, et al. Among authors: jarlier m. Clin Cancer Res. 2017 Jun 1;23(11):2806-2816. doi: 10.1158/1078-0432.CCR-16-1316. Epub 2016 Dec 6. Clin Cancer Res. 2017. PMID: 27923843
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P, Fontayne A, Barret JM, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget JP, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost JF, Pèlegrin A, Navarro-Teulon I. Estupina P, et al. Among authors: jarlier m. Oncotarget. 2017 Jun 6;8(23):37061-37079. doi: 10.18632/oncotarget.15715. Oncotarget. 2017. PMID: 28427157 Free PMC article.
66 results